X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

ICON Announces the Expansion of its Accellacare Site Network

Content Team by Content Team
19th November 2021
in Press Statements
ICON Announces the Expansion of its Accellacare Site Network

ICON plc, a global provider of drug development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, announced that its Accellacare Site Network has expanded in reach and capabilities through new partnerships with six research sites across four countries.

Agreements with Asclepes Research and Olympian Clinical Research in the United States, Curiositas ad Sanum and Intermed in Germany, Quironsalud in Spain, and KO-MED in Poland brings the Accellacare network to 112 active locations across eight countries and the entry to two new U.S. states – Florida and California. Through these new partnerships, Accellacare is also enhancing its already-strong capability in the central nervous system (CNS) and immune-inflammation therapeutic areas.

The expansion of the Accellacare Site Network increases access and engagement with investigative sites and its patients, supporting faster recruitment and reducing the overall time and cost associated with drug development for customers. Accellacare now has access to more than 9 million patients.

“Enrolling and engaging patients in clinical trials continues to be one of the biggest challenges within drug development,” said Alison Liddy, Senior Vice President, Site & Patient Solutions at ICON. “Our new Accellacare partnerships extend our ability to help customers enhance clinical trial feasibility and improve patient enrollment timelines in key therapeutic areas. We are committed to enhancing engagement with sites, patients and healthcare providers to reduce the overall time and costs of clinical development programmes for our customers.”

ICON launched Accellacare, a global clinical research network, in September 2020, providing patients easier and faster access to innovative treatments and offering customers the option to deploy decentralised trials. For customers, this approach leads to higher patient recruitment and retention rates, which generates operational efficiencies, accelerates study start-up timelines, and enhances study feasibility.

“As the clinical trial industry evolves past the COVID-19 pandemic, it is more important than ever to ensure we have a strong partner to continue to enable growth at our sites,” said Tim Welke, owner of Asclepes Research Centers. “Over the last several months, Accellacare has been a valuable member of our operation, allowing us to have more studies to offer our patients. Accellacare’s commitment and support to our site and each study aligns with our mission of improving patient care.”

About ICON plc and Accellacare
ICON is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON operates from 159 locations in 53 countries and has approximately 37,960 employees as of September 30, 2021.

Accellacare is a global clinical research network incorporating the Accellacare Site Network, In-Home Services and Site Resourcing. The Accellacare Site Network extends to 112 active research sites in eight countries with expertise in a wide range of therapeutic areas. It has relationships with more than 300 Principal Investigators, which connects the network to 9 million patients across its footprint.

Previous Post

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

Next Post

Birmingham Biotech and the University of Birmingham Sign Licensing Agreement for Anti-Viral Nasal Spray Against COVID-19

Related Posts

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
Europe

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

3rd March 2023
Canada's National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero
Manufacturing

Canada’s National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero

22nd February 2023
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine
Drug Development

Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China

21st February 2023
Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea
Clinical Trials

Labcorp Unveils New Name for Future Independent Clinical Development Business – Fortrea

21st February 2023
Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance
IPR Data Management

Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance

21st February 2023
West Expands Corning Collaboration and Launches First Product
Packaging & Logistic

West Expands Corning Collaboration and Launches First Product

21st February 2023
Next Post
Glenmark and SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

Birmingham Biotech and the University of Birmingham Sign Licensing Agreement for Anti-Viral Nasal Spray Against COVID-19

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In